Navigation Links
Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 5, 2007 - Repros Therapeutics Inc. (NasdaqGM:RPRX) announced topline results of a six month U.S. Phase 3 study of Androxal(TM), an oral drug being developed to restore normal testicular function in men with secondary hypogonadism. Further, Androxal demonstrates non-inferiority in all the endpoints of the study, compared to Androgel(R), a cream which is the leading treatment for low testosterone.

Study Details and Results

This six month, double-blind study compared two doses of oral Androxal, 12.5mg and 25mg, to matching placebo capsules and open label Androgel at any dose to be used per manufacturer's instructions. The study's primary efficacy endpoint was the proportion of patients at month three who showed morning total serum testosterone concentrations within the normal physiological range (300 to 1040 ng/dl). This endpoint was also extended to include the outcome at month six as well as the assessment of non-inferiority to Androgel.

Of the 191 patients enrolled in the trial, 144 patients completed the study. There were 8 and 15 premature drop outs in the 12.5mg and 25mg Androxal arms, respectively, 15 drop outs in the placebo arm, and 13 drop outs in the Androgel arm. There were no drop outs due to an adverse event or lack of compliance in the Androxal treatment groups. The majority of the other drop outs were due to either withdrawal of consent or "lost to follow-up". There were 188 patients in the modified intent-to-treat group ("MITT") consisting of all randomized patients with at least one efficacy evaluation.

The proportion of men in the 12.5mg and 25mg treatment arms with total testosterone in the physiological range at month three using the last observation carried forward was 72.7% and 79.2%, respectively, and those on Androgel and placebo the proportion was 57.4% and 28.3%, respectively. These results confirm non-inferiority to Androge
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
7. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
8. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
9. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
10. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
11. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... N.C., Feb. 10, 2012  Viztek, the digital radiology solution ... U-Arm at Edison Metuchen Orthopaedic Group (EMOG) in Edison, ... psychiatrist with onsite x-ray and access to an MRI facility ... EMOG performs between 65 and 85 x-ray procedures ...
... PRINCETON, N.J., Feb. 10, 2012 Soligenix, Inc. ... stage biopharmaceutical company, announced preliminary results today from ... time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), ... The Phase 1/2 protocol BDP-ENT-01 was ...
Cached Medicine Technology:Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 2Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 3Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 4Soligenix Announces Results From Its Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 5
(Date:4/18/2014)... University School of Medicine researchers have been awarded two-year ... Novo Nordisk announced this month. Of the 110 initial ... Biologics Science Forum Program, only four projects were funded, ... They are Jonathan Powell, M.D., Ph.D.; G. William Wong, ... Powell, a professor of oncology, will use his $500,000 ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... to potential new treatments for breaking the cycle of ... or scarring, is a hallmark of the disease, and ... to serious organ damage and, in some cases, death. ... findings made by Swati Bhattacharyya, PhD, research assistant professor ... protein plays in promoting fibrosis. , "Our results ...
(Date:4/17/2014)... identified the first genetic variant specifically associated with ... for around 10-15 per cent of all breast ... the breast cancer sub-type, called invasive lobular carcinoma, ... of this particular kind of breast cancer, which ... published today (Thursday) in the journal PloS ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2
... 23 (HealthDay News) -- Implantable devices designed to ... death among heart failure patients are as effective ... they are in controlled study environments, new research ... analysis of nearly 186,000 patients outfitted with either ...
... Richmond, Va. (Nov. 22, 2010) Researchers at Virginia ... for its involvement in tumor cell development, growth and ... chemotherapy. By inhibiting the expression of this gene, doctors ... treating aggressive cancers such as breast, liver and prostate ...
... Elderly adults can improve their vision with perceptual training, according ... Boston University that has implications for the health and mobility ... improved visual performance in early stages of visual processing," appears ... Vision . It was funded by a $3.5 million grant ...
... News) -- Increased efforts to prevent several lifestyle-related diseases ... year in medical costs, researchers say. Using 2003-2005 ... estimated how reductions in the rates of diabetes, high ... spending. The findings were released online Nov. 18 ...
... HealthDay Reporter , MONDAY, Nov. 22 (HealthDay ... therapy with either warfarin or a combination of Plavix ... Both therapies are prescribed for millions of Americans ... attack or stroke. But the Plavix-aspirin combination was thought ...
... and droplets are the primary ways influenza spreads. ... In a study published in the current issue ... ( http://www.journals.uchicago.edu/doi/abs/10.1086/656743 ), the authors examined such an ... On April 4, 2008, seven inpatients in ...
Cached Medicine News:Health News: Implanted Heart Devices Have 'Real-World' Benefits: Study 2Health News: Implanted Heart Devices Have 'Real-World' Benefits: Study 3Health News:New function of gene in promoting cancer found by VCU researchers 2Health News:Perceptual training improves vision of the elderly 2Health News:Disease Prevention Could Save U.S. Billions of Dollars Annually 2Health News: Bleeding Risk With Plavix-Aspirin Regimen May Be Serious 2Health News: Bleeding Risk With Plavix-Aspirin Regimen May Be Serious 3
... with BD Xstar Blade includes a specially ... blade in prodedure and handling. The ... grind-less process for manufacturing surgical blades. ... consistency. The arch style, single-bevel geometry ...
... Knife with BD Xstar Blade includes a ... the blade in prodedure and handling. ... a grind-less process for manufacturing surgical blades. ... and consistency. The arch style, single-bevel ...
Bio-Rad's Genetic Systems HIV-1/HIV-2 PLUS O EIA is a unique assay that detects the broadest range of HIV....
An advanced microprocessor-controlled unit with superior reliability and reproducible power. Its modern electronics provides the precision and control a surgeon expects....
Medicine Products: